High Unmet Needs Exist in Alzheimer’s Disease Therapeutics Market, States GBI Research in New Topical Study Recently Added at MarketPublishers.com25 Jan 2017 • by Natalie Aster
LONDON - Alzheimer’s disease (AD) is recognised as a progressive, irreversible neurodegenerative disease, characterised by memory loss, functional decline and cognitive impact. The pathological feature of this disease include a range of histopathological changes within the brain. First symptoms typically appear in patients after 60 years old. The effects of Alzheimer’s disease, especially at an advanced stage, are devastating both to patients and caregivers, and are associated with considerable healthcare costs.
Modern treatments tend to focus on sustaining a patient’s cognitive function, slowing down the rate of disease progression as well as managing behavioural symptoms. Unfortunately, there is presently no cure for Alzheimer’s disease. Only 6 symptomatic treatment therapies are approved. Therefore, there are still high unmet needs within the Alzheimer’s disease therapeutics market.
There are many differences between various therapeutic products owing to their mechanisms of action. These must be clearly understood by companies intending to position a new drug in the Alzheimer’s disease therapeutics market.
All the important aspects of this market are covered in the cutting-edge research report “Alzheimer's Disease - Heat Map and Analysis” elaborated by GBI Research. This publication, gives trustworthy information on all late-stage clinical trials for products in the Alzheimer’s disease therapeutics market and also provides insights into Phase III pipeline. It discusses all safety and efficacy endpoints for drug and placebo groups. The report includes an overview of the clinical benchmarks set by the present market landscape and also touches upon the expected changes; reviews the currently approved drugs, identifies the unmet needs.
To find many other topical research reports prepared by GBI Research, visit this Market Publishers’ catalogue.